このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Immunome マネジメント

マネジメント基準チェック /14

Immunome'sの CEO はClay Siegallで、 Oct2023年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 15.65Mで、 1%給与と99%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.7%を直接所有しており、その価値は$ 5.52M 。経営陣と取締役会の平均在任期間はそれぞれ0.7年と3年です。

主要情報

Clay Siegall

最高経営責任者

US$15.6m

報酬総額

CEO給与比率	1.0%
CEO在任期間	less than a year
CEOの所有権	0.7%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	3yrs

経営陣の近況

Recent updates

CEO報酬分析

Immunome の収益と比較して、Clay Siegall の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$232m
Dec 31 2023	US$16m	US$163k	-US$107m

報酬と市場: Clayの総報酬 ($USD 15.65M ) は、 US市場 ($USD 3.40M ) の同規模の企業の平均を上回っています。

報酬と収益: Clayの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Clay Siegall (63 yo)

less than a year

在職期間

US$15,648,944

報酬

Dr. Clay B. Siegall, Ph D., serves as Independent Chairman since December 13, 2023 at Tourmaline Bio, Inc. He served as Chief Executive Officer & President of Morph Immune, Inc. from March 2023 until Octob...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Clay Siegall	President	less than a year	US$15.65m	0.70% $ 5.2m
Jack Higgins	Chief Scientific Officer	less than a year	US$2.17m	0% $ 0
Robert Lechleider	Chief Medical Officer	less than a year	US$3.22m	データなし
Max Rosett	Executive VP of Operations	less than a year	データなし	0.033% $ 247.0k
Philip Tsai	Chief Technology Officer	no data	データなし	データなし
Sandra Stoneman	Chief Legal Officer	3.7yrs	US$1.64m	0.0093% $ 69.1k
Bruce Turner	Chief Strategy Officer	less than a year	データなし	0.071% $ 526.2k
Kinney Horn	Chief Business Officer	less than a year	データなし	データなし

0.7yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: IMNMの経営陣は経験豊富とはみなされません ( 0.7年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Clay Siegall	President	less than a year	US$15.65m	0.70% $ 5.2m
Louis Weiner	Member of Scientific Advisory Board	no data	データなし	データなし
Philip Wagenheim	Director	6.5yrs	US$59.23k	0.65% $ 4.9m
George Prendergast	Member of Scientific Advisory Board	no data	データなし	データなし
Isaac Barchas	Lead Independent Director	less than a year	US$296.59k	0.15% $ 1.1m
James Boylan	Independent Director	less than a year	US$294.75k	0% $ 0
Andrew Badley	Member of COVID-19 Advisory Board	3yrs	データなし	データなし
Carol Schafer	Independent Director	less than a year	データなし	0% $ 0
William Strohl	Member of Scientific Advisory Board	no data	データなし	データなし
Jeffrey Henderson	Member of COVID-19 Advisory Board	3.8yrs	データなし	データなし
Shmuel Shoham	Member of COVID-19 Advisory Board	3.8yrs	データなし	データなし
Susan Weiss	Member of COVID-19 Advisory Board	3.8yrs	データなし	データなし

3.0yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: IMNMの取締役会は経験豊富であると考えられます ( 3年の平均在任期間)。

Immunome マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

President recently bought US$1.4m worth of stock

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Recent updates

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01

Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01

New 90-day high: US$20.24

Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares

New 90-day high: US$13.73

Immunome, Inc. Appoints Diane Marcou as Interim Chief Financial Officer

Immunome EPS misses by $7.22

Key Executive recently bought US$1m worth of stock

Immunome, Inc. has completed an IPO in the amount of $39 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

マネジメント基準チェック /14